DeBeurs.nl

uniQure Terug naar discussie overzicht

AAV5

3 Posts
| Omlaag ↓
  1. Vitavita 2 juli 2017 14:48
    "...and other severe diseases"

    ~ Updated, Long-term Results from the Phase I/II Dose-Escalating Study of AMT-
    060 to be Presented on Monday, July 10, 2017 ~

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 23, 2017 (GLOBE NEWSWIRE)
    -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing
    transformative therapies for patients with severe medical needs, today announced
    that two abstracts have been accepted for presentation at the International
    Society on Thrombosis and Hemostasis (ISTH) Congress held in Berlin, Germany,
    July 8 - 13, 2017.

    "The data to be featured in an oral presentation at ISTH now demonstrate long-
    term safety, efficacy and the potential for broad application of AAV5 in
    hemophilia B," stated Matthew Kapusta, chief executive officer of uniQure. "We
    also look forward to the presentation of clinical data demonstrating successful
    and effective transduction in patients with pre-existing neutralizing antibodies
    to AAV5, further supporting our belief that our AAV5-based gene therapies may
    provide clinical benefits to nearly all patients suffering from hemophilia B and
    other severe diseases
    ."
  2. Vitavita 31 juli 2017 17:45
    @ Prof. Dollar: "Dat Chiesi niet de big pharma is waarmee de wereld wordt veroverd daarin kan ik mij vinden. Aan welke 'potential opportunities' die nota bene gerelateerd zijn aan het programma zouden ze denken?"

    ..deze cliffhanger hebben we ook nog staan...

    "and other severe diseases"

3 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van DeBeurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 467 7.733
AB InBev 3 5.624
Abionyx Pharma 2 29
Ablynx 43 13.357
ABN AMRO 1.583 55.265
ABO-Group 1 28
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 268
Accsys Technologies 24 12.479
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 204
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 15 18.883
Aedifica 3 1.036
Aegon 3.259 324.784
AFC Ajax 538 7.132
Affimed NV 2 6.358
ageas 5.845 109.981
Agfa-Gevaert 15 2.161
Ahold 3.542 74.578
Air France - KLM 1.026 35.957
AIRBUS 1 15
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 469 13.313
Alfen 18 29.195
Allfunds Group 4 1.752
Almunda Professionals (vh Novisource) 651 4.282
Alpha Pro Tech 1 17
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.487 114.840
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.861 252.597
AMG 973 140.455
AMS 3 73
Amsterdam Commodities 307 6.908
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 579
Antonov 22.632 153.607
Aperam 93 15.653
Apollo Alternative Assets 1 17
Apple 5 409
Arcadis 254 9.829
Arcelor Mittal 2.044 322.232
Archos 1 1
Arcona Property Fund 1 305
arGEN-X 18 11.826
Aroundtown SA 1 251
Arrowhead Research 5 9.954
Ascencio 1 38
ASIT biotech 2 697
ASMI 4.109 40.848
ASML 1.769 129.720
ASR Nederland 21 4.610
ATAI Life Sciences 1 7
Atenor Group 1 556
Athlon Group 121 176
Atos 4 3.506
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 35 17.793
Axsome Therapeutics 1 177
Azelis Group 2 9
Azelis Group NV 2 165
Azerion 7 3.835